The truth is, once the data has been discussed elsewhere and in a journal, it is no longer acceptable at ASCO as it is not new information. If either the company or the clinicians had something that has never been presented, then an Abstract could be submitted and be likely to be accepted for presentation at ASCO or similar major conferences.
I don't know that Flaskworks has ever been presented, but I don't think ASCO is necessarily the best conference to present it at. New data on combination of DCVAX-L and other therapeutics could be presented, but they are trials that UCLA is running, not sponsored by NWBO, so I believe it is up to them when and where to present it. Let's see if anything shows up when the Abstracts are revealed.
Gary
Market Data 
Markets 
AI
